My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

Nerds Words: 2022 Heart Failure Guidlines

Horizontales
Class I for HFrEF. Exhibited benefits comparable to enalapril in the VALIANT trial
Class I for those with EF ≤ 40%. Has been shown to impede adverse remodeling in reduced EF after an MI
BONUS GUIDELINE (ISHLT 2022): Many transplant pts have this level measured in the morning. Inhibits CYP3A4, and so need to watch for drug interactions
One of two antiarrhythmics with netural effect on mortality in HFrEF trials
Production blocked by 1 Across and 3 Across
The MADIT-II trial showed that primary prevention ICD implantation in those with prior MI and advanced LV dysfunction reduced this, for short
Class I rec, but only for those not responding to moderate or high-dose loop diuretics
Eplerenone is one of these. Class III if serum potassium cannot be maintained <5.5 mEq/L
Class IIa recommended in the diagnosis of HF. Helpful in processes such as amyloid, where diffuse late gadolnium enhancement may be seen
Levels are increased by 27 Across. Potential beneficial effects include decreased fibrosis, vasodilation, and improved endothelial function
BONUS GUIDELINE (ISHLT 2022): An HLA antibody check, for short. Class IIa to mesure when antibody-mediated rejection is suspected.
Class I to measure in newly diagnosed HF (though some disagree with this commonly used abbreviation)
Class I for HFrEF and NYHA Class II-IV if K < 5.0 mEq/L and eGFR >30 mL/min
Class IIa recommended in ambulatory pts with HF to assess functional capacity
BONUS GUIDELINE! ______-phic cardiomyopathy remains a more common condition than many realize with a prevalence from 1:200 - 1:500. Inherited in autosomal dominant pattern
Drug studied in the VICTORIA trial. Class IIa for selected HFrEF patients already on GDMT
Class IIb for HFrEF unable to tolerate first-line agents, but only when given with hydralazine
Must have this for 35 Down to be a Class I recommendation
May optimize an LVAD with this type of study
Nondihydropyridines may reduce this, and so are Class III with EF <50%.
This class of medication led to a greater reduction in NT-proBNP in the PIONEER-HF trial than enalapril without significantly different rates in worse renal function or hyperkalemia. Class III if given within 36 hours of last dose of ACEi!
Might lead to Na and water retention and so requires caution in HF
Trial that showed pts with ischemic or nonischemic CM, EF ≤35%, and Class II or III symptoms benefit from ICD placement
Noninvasive test that is Class IIb in pts with HF and CAD who are candidates for coronary revascularization to help guide management
A good place to meet guideline recs, but might also need a membership
Verticales
Class I for HFrEF, but not HFpEF
The place for a drug, or a student
Class I in initial evaluation of suspected HF
This Class IIa recommended rehab can be useful to improve functional capacity
Kansas City Cardiomyopathy Questionaire measures this, for short
Class I for those with EF ≤35% on chronic GDMT, NYHA Class II-III, and ≥ 1 year survival expected
Ivabradine blocks I-funny currents at the sinus ____
Re-evaluation of EF to determine ICD or CRT candidancy is recommended >90 days after placement of this when used for revascularization
Important option for advanced HF with hemodynamic compromise or shock, for short
Sometimes also called the Four Pillars of HFrEF management
May signal cardiogenic shock when this measurement of right heart function is <2.0 (Abbreviation)
Two of these inhibitors, saxagliptin and alogliptin, are recommended to stop by the FDA upon HF development
The other one from 8 Across clue
Diet inversely associated with incident HF per guidelines
≥50% obstruction of the ____ main and LV dysfunction should really go to CABG per guidelines
Inhibits resorption of Na or Cl at the loop of Henle. TRANSFORM-HF trial featuring this showed no significant difference in all-cause mortality over 12 months when compared to a similar frequently used HF medication
Class I to obtain in those presenting with acute decompensated HF
Class I to check in those presenting with dyspnea
Important to flush these properly and zero the transducer to obtain accurate readings when placing pulmonary artery cath
Receptor activated by Thiazolidinediones (Which are associated with increased HF events and Class III in HFrEF per guidelines)
Maybe an upgrade for 9 down for EF ≤35% and QRS ≥150ms
BONUS GUIDELINE (2021 Revasc) The benefits of opening this remains uncertain, and are class IIb in revascularization guidelines